Pharmacotherapy of scleromyxedema

References

• Rongioletti F, Rebora A. Updated classification of papular mucinosis, lichen myxedematosus, and scleromyxedema. J Am Acad Dermatol 2001;44:273-81
   PubMed Web of Science ®Google Scholar
• Dermatology, Mucinoses. 2nd edition. Rongioletti F, Rebora A, Bolognia J, et al. editors. Elsevier Saunders, Spain; 2012
   Google Scholar
• Rongioletti F, Merlo G, Cinotti E, et al. Scleromyxedema: a multicenter study of characteristics, comorbidities, course, and therapy in 30 patients. J Am Acad Dermatol 2013;69:66-72
   PubMed Web of Science ®Google Scholar
• Dinneen AM, Dicken CH. Scleromyxedema. J Am Acad Dermatol 1995;33:37-43
   PubMed Web of Science ®Google Scholar
• Harper RA, Rispler J. Lichen myxedematosus serum stimulates human skin fibroblast proliferation. Science 1978;199:545-7
   PubMed Web of Science ®Google Scholar
• Migkou M, Gkotzamanidou M, Terpos E, et al. Response to bortezomib of a patient with scleromyxedema refractory to other therapies. Leuk Res 2011;35:e209-11
   PubMed Web of Science ®Google Scholar
• Boffa MJ, Ead RD. Spontaneous improvement of scleromyxoedema. Clin Exp Dermatol 1995;20:157-60
   PubMed Web of Science ®Google Scholar
• Feldman P, Shapiro L, Pick AI, et al. Scleromyxedema. A dramatic response to melphalan. Arch Dermatol 1969;99:51-6
   PubMedGoogle Scholar
• Hadida E, Sayag J. Arndt-Gottron scleromyxedema; treatment with melphalan. Arch Belg Dermatol Syphiligr 1969;25:299-304
   PubMedGoogle Scholar
• Do Prado AD, Schmoeller D, Bisi MC, et al. Scleromyxedema with monoclonal gammopathy and neurological involvement: recovery from coma after plasmapheresis? Int J Dermatol 2012;51:1013-15
   PubMed Web of Science ®Google Scholar
• Jessen RT, Straight M, Becker LE. Lichen myxedematosus. Treatment with cyclophosphamide. Int J Dermatol 1978;17:833-9
   PubMedGoogle Scholar
• Howsden SM, Herndon JH Jr, Freeman RG. Lich myxedematosus. A dermal infiltrative disorder responsive to cyclophosphamide therapy. Arch Dermatol 1975;111:1325-30
   PubMedGoogle Scholar
• Kuldeep CM, Mittal AK, Gupta LK, et al. Successful treatment of scleromyxedema with dexamethasone cyclophosphamide pulse therapy. Indian J Dermatol Venereol Leprol 2005;71:44-5
   PubMedGoogle Scholar
• Aberer W, Wolff K. Scleromyxedema: immunosuppressive therapy with cyclophosphamide. Hautarzt 1988;39:277-80
   PubMed Web of Science ®Google Scholar
• Helfrich DJ, Walker ER, Martinez AJ, et al. Scleromyxedema myopathy: case report and review of the literature. Arthritis Rheum 1988;31:1437-41
   PubMedGoogle Scholar
• Breuckmann F, Freitag M, Rotterdam S, et al. Immunohistochemical investigations and introduction of new therapeutic strategies in scleromyxoedema: case report. BMC Dermatol 2004;22:4-12
   Google Scholar
• Lopez L, Wierzbicka-Hainaut E, Villers A, et al. Efficacy of intravenous immunoglobulin in Arndt-Gottron scleromyxedema. Ann Dermatol Venereol 2009;136:330-6
   PubMedGoogle Scholar
• Mehta V, Balachandran C, Rao R. Arndt Gottron scleromyxedema: successful response to treatment with steroid minipulse and methotrexate. Indian J Dermatol 2009;54:193-5
   PubMedGoogle Scholar
• Schirren CG, Betke M, Eckert F, et al. Arndt-Gottron scleromyxedema. Case report and review of therapeutic possibilities. Hautarzt 1992;43:152-7
   PubMedGoogle Scholar
• Krasagakis K, Zouboulis CC, Owsianowski M, et al. Remission of scleromyxoedema following treatment with extracorporeal photopheresis. Br J Dermatol 1996;135:463-6
   PubMed Web of Science ®Google Scholar
• Wieder JM, Barton KL, Baron JM, et al. Lichen myxedematosus treated with chlorambucil. J Dermatol Surg Oncol 1993;19:475-6
   PubMedGoogle Scholar
• Davis LS, Sanal S, Sangueza OP. Treatment of scleromyxedema with 2-chlorodeoxyadenosine. J Am Acad Dermatol 1996;35:288-90
   PubMedGoogle Scholar
• Wright RC, Franco RS, Denton D, et al. Scleromyxedema. Arch Dermatol 1976;112:63-6
   PubMedGoogle Scholar
• Rayson D, Lust JA, Duncan A, et al. Scleromyxedema: a complete response to prednisone. Mayo Clin Proc 1999;74:481-4
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Molecular mechanisms and cellular effects of glucocorticosteroids. Immunol Allergy Clin North Am 2005;25:451-68
   PubMed Web of Science ®Google Scholar
• Silvestri M, Sabatini F, Scarso L, et al. Fluticasone propionate downregulates nasal fibroblast functions involved in airway inflammation and remodeling. Int Arch Allergy Immunol 2002;128:51-8
   PubMed Web of Science ®Google Scholar
• Lin Y-C, Wang H-C, Shen J-L. Scleromyxedema: an experience using treatment with systemic corticosteroid and review of the published work. J Dermatol 2006;33:207-10
   PubMed Web of Science ®Google Scholar
• Horn KB, Horn MA, Swan J, et al. A complete and durable clinical response to high-dose dexamethasone in a patient with scleromyxedema. J Am Acad Dermatol 2004;51:S120-3
   PubMed Web of Science ®Google Scholar
• Kreuter A, Scola N, Tigges C, et al. Clinical features and efficacy of antimalarial treatment for reticular erythematous mucinosis: a case series of 11 patients. Arch Dermatol 2011;147:710-15
   PubMedGoogle Scholar
• Rongioletti F, Hazini A, Rebora A. Coma associated with scleromyxoedema and interferon alfa therapy. Full recovery after steroids and cyclophosphamide combined with plasmapheresis. Br J Dermatol 2001;144:1283-4
   PubMed Web of Science ®Google Scholar
• Rampino M, Garibaldi E, Ragona R, et al. Scleromyxedema: treatment of widespread cutaneous involvement by total skin electron-beam therapy. Int J Dermatol 2007;46:864-7
   PubMed Web of Science ®Google Scholar
• Hill TG, Crawford JN, Rogers CC. Successful management of lichen myxedematosus. Report of a case. Arch Dermatol 1976;112:67-9
   PubMedGoogle Scholar
• Lowe NJ, Dufton PA, Hunter RD, et al. Electron-beam treatment of scleromyxoedema. Br J Dermatol 1982;106:449-53
   PubMed Web of Science ®Google Scholar
• Harris RB, Perry HO, Kyle RA, et al. Treatment of scleromyxedema with melphalan. Arch Dermatol 1979;115:295-9
   PubMedGoogle Scholar
• Koeppel MC, Aquilina C, Terrier G, et al. Electron-beam therapy in Arndt-Gottron's scleromyxoedema. Br J Dermatol 1993;129:733-5
   PubMed Web of Science ®Google Scholar
• Leung SW, Hsu HC, Huang PH. Total skin electron beam irradiation in scleromyxoedema. Br J Radiol 1998;71:84-6
   PubMed Web of Science ®Google Scholar
• Adachi Y, Iba S, Horio T. Successful treatment of lichen myxoedematosus with PUVA photochemotherapy. Photodermatol Photoimmunol Photomed 2000;16:229-31
   PubMed Web of Science ®Google Scholar
• Farr PM, Ive FA. PUVA treatment of scleromyxoedema. Br J Dermatol 1984;110:347-50
   PubMed Web of Science ®Google Scholar
• Penmetcha M, Highet AS, Hopkinson JM. Failure of PUVA in lichen myxoedematosus: acceleration of associated multiple keratoacanthomas with development of squamous carcinoma. Clin Exp Dermatol 1987;12:220-3
   PubMed Web of Science ®Google Scholar
• Yamazaki S, Fujisawa T, Yanatori A, et al. A case of lichen myxedematosus with clearly exacerbated skin eruptions after UVB irradiation. J Dermatol 1995;22:590-3
   PubMedGoogle Scholar
• Hisler BM, Savoy LB, Hashimoto K. Improvement of scleromyxedema associated with isotretinoin therapy. J Am Acad Dermatol 1991;24:854-7
   PubMed Web of Science ®Google Scholar
• Milam CP, Cohen LE, Fenske NA, et al. Scleromyxedema: therapeutic response to isotretinoin in three patients. J Am Acad Dermatol 1988;19:469-77
   PubMed Web of Science ®Google Scholar
• Brenner S, Yust I. Treatment of scleromyxedema with etretinate. J Am Acad Dermatol 1984;10:295-6
   PubMed Web of Science ®Google Scholar
• Lominska-Lasota K, Rosen-Uzelac G, Reichl W, et al. Scleromyxedema therapy with isotretinoin. Z Hautkr 1988;63:137-8.141
   PubMedGoogle Scholar
• Tschen JA, Chang JR. Scleromyxedema: treatment with interferon alfa. J Am Acad Dermatol 1999;40:303-7
   PubMed Web of Science ®Google Scholar
• Keong CH, Asaka Y, Fukuro S, et al. Successful treatment of scleromyxedema with plasmapheresis and immunosuppression. J Am Acad Dermatol 1990;22:842-4
   PubMed Web of Science ®Google Scholar
• Westheim AI, Lookingbill DP. Plasmapheresis in a patient with scleromyxedema. Arch Dermatol 1987;123:786-9
   PubMedGoogle Scholar
• Reid TL, Spoto DV, Larrabee GJ, et al. Monoclonal paraproteinemia with subacute encephalopathy, seizures, and scleromyxedema. Neurology 1987;37:1054-7
   PubMedGoogle Scholar
• Nieves DS, Bondi EE, Wallmark J, et al. Scleromyxedema: successful treatment of cutaneous and neurologic symptoms. Cutis 2000;65:89-92
   PubMed Web of Science ®Google Scholar
• Owsianowski M, Garbe C, Ramaker J, et al. Therapeutic experiences with extracorporeal photopheresis. Technical procedure, follow-up and clinical outcome in 31 skin diseases. Hautarzt 1996;47:114-23
   PubMedGoogle Scholar
• D'Incan M, Franck F, Kanold J, et al. Cutaneo-systemic papulosclerotic mucinosis (scleromyxedema): remission after extracorporeal photochemotherapy and corticoid bolus. Ann Dermatol Venereol 2001;128:38-41
   PubMedGoogle Scholar
• Durani BK, Bock M, Näher H. Extracorporeal photopheresis--treatment option in scleromyxedema? Hautarzt 2001;52:938-41
   PubMed Web of Science ®Google Scholar
• Cohen AM, Hodak E, David M, et al. Beneficial effect of granulocyte-colony stimulating factor in scleromyxoedema associated with severe idiopathic neutropenia. Br J Dermatol 1996;135:626-9
   PubMed Web of Science ®Google Scholar
• Krajnc I. Arndt-Gottron scleromyxedema. Summary of 2 years treatment. Wien Klin Wochenschr 1997;109:960-3
   PubMedGoogle Scholar
• Bata-Csorgo Z, Husz S, Foldes M, et al. Scleromyxedema. J Am Acad Dermatol 1999;41:343-6
   PubMedGoogle Scholar
• Saigoh S, Tashiro A, Fujita S, et al. Successful treatment of intractable scleromyxedema with cyclosporin A. Dermatology (Basel) 2003;207:410-11
   PubMed Web of Science ®Google Scholar
• Ozdag F, Akar A, Eroglu E, et al. Acute rhabdomyolysis during the treatment of scleromyxedema with interferon alfa. J Dermatolog Treat 2001;12:167-9
   PubMed Web of Science ®Google Scholar
• Kumar N, Rodriguez M. Scleromyxedema in a patient with multiple sclerosis and monoclonal gammopathy on interferon beta-1a. Mult Scler 2004;10:85-6
   PubMedGoogle Scholar
• Negi V-S, Elluru S, Sibéril S, et al. Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol 2007;27:233-45
   PubMed Web of Science ®Google Scholar
• Lister RK, Jolles S, Whittaker S, et al. Scleromyxedema: response to high-dose intravenous immunoglobulin (hdIVIg). J Am Acad Dermatol 2000;43:403-8
   PubMed Web of Science ®Google Scholar
• Blum M, Wigley FM, Hummers LK. Scleromyxedema: a case series highlighting long-term outcomes of treatment with intravenous immunoglobulin (IVIG). Medicine (Baltimore) 2008;87:10-20
   PubMed Web of Science ®Google Scholar
• Jolles S, Hughes J, Rustin M. Intracellular interleukin-4 profiles during high-dose intravenous immunoglobulin treatment of therapy-resistant atopic dermatitis. J Am Acad Dermatol 1999;40:121-3
   PubMed Web of Science ®Google Scholar
• Bayry J, Misra N, Latry V, et al. Mechanisms of action of intravenous immunoglobulin in autoimmune and inflammatory diseases. Transfus Clin Biol 2003;10:165-9
   PubMed Web of Science ®Google Scholar
• Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 2001;291:484-6
   PubMed Web of Science ®Google Scholar
• Schwab I, Nimmerjahn F. Intravenous immunoglobulin therapy: how does IgG modulate the immune system? Nat Rev Immunol 2013;13:176-89
   PubMed Web of Science ®Google Scholar
• Baerenwaldt A, Biburger M, Nimmerjahn F. Mechanisms of action of intravenous immunoglobulins. Expert Rev Clin Immunol 2010;6:425-34
   PubMed Web of Science ®Google Scholar
• Prins C, Gelfand EW, French LE. Intravenous immunoglobulin: properties, mode of action and practical use in dermatology. Acta Derm Venereol 2007;87:206-18
   PubMed Web of Science ®Google Scholar
• Gholam P, Hartmann M, Enk A. Arndt-Gottron scleromyxoedema: successful therapy with intravenous immunoglobulins. Br J Dermatol 2007;157:1058-60
   PubMedGoogle Scholar
• Körber A, Franckson T, Grabbe S, et al. Successful therapy of scleromyxoedema Arndt-Gottron with low-dose intravenous immunoglobulin. J Eur Acad Dermatol Venereol 2007;21:553-4
   PubMedGoogle Scholar
• Righi A, Schiavon F, Jablonska S, et al. Intravenous immunoglobulins control scleromyxoedema. Ann Rheum Dis 2002;61:59-61
   PubMedGoogle Scholar
• Roque Diamantino F de E, Lopes João AMB, Clemente Fidalgo AIP, et al. Treatment of scleromyxedema with intravenous immunoglobulin. Eur J Dermatol 2010;20:861-2
   PubMedGoogle Scholar
• Bidier M, Zschoche C, Gholam P, et al. Scleromyxoedema: clinical follow-up after successful treatment with high-dose immunoglobulins reveals different long-term outcomes. Acta Derm Venereol 2012;92:408-9
   PubMed Web of Science ®Google Scholar
• Shergill B, Orteu CH, McBride SR, et al. Dementia associated with scleromyxoedema reversed by high-dose intravenous immunoglobulin. Br J Dermatol 2005;153:650-2
   PubMed Web of Science ®Google Scholar
• Binitha MP, Nandakumar G, Thomas D. Suspected cardiac toxicity to intravenous immunoglobulin used for treatment of scleromyxedema. Indian J Dermatol Venereol Leprol 2008;74:248-50
   PubMed Web of Science ®Google Scholar
• Vesole DH. Transplantation for multiple myeloma: who, when, how often? Patient selection and goals. Blood 200:15:102-3471–2
   Google Scholar
• Feasel AM, Donato ML, Duvic M. Complete remission of scleromyxedema following autologous stem cell transplantation. Arch Dermatol 2001;137:1071-2
   PubMedGoogle Scholar
• Lacy MQ, Hogan WJ, Gertz MA, et al. Successful treatment of scleromyxedema with autologous peripheral blood stem cell transplantation. Arch Dermatol 2005;141:1277-82
   PubMedGoogle Scholar
• Illa I, de la Torre C, Rojas-Garcia R, et al. Steady remission of scleromyxedema 3 years after autologous stem cell transplantation: an in vivo and in vitro study. Blood 2006;108:773-4
   PubMed Web of Science ®Google Scholar
• Bos R, de Waal EGM, Kuiper H, et al. Thalidomide and dexamethasone followed by autologous stem cell transplantation for scleromyxoedema. Rheumatology (Oxford) 2011;50:1925-6
   PubMed Web of Science ®Google Scholar
• Cañueto J, Labrador J, Román C, et al. The combination of bortezomib and dexamethasone is an efficient therapy for relapsed/refractory scleromyxedema: a rare disease with new clinical insights. Eur J Haematol 2012;88:450-4
   PubMed Web of Science ®Google Scholar
• Iranzo P, López-Lerma I, Bladé J, et al. Scleromyxoedema treated with autologous stem cell transplantation. J Eur Acad Dermatol Venereol 2007;21:129-30
   PubMed Web of Science ®Google Scholar
• Terheyden P, Becker JC, Lurz C, et al. Treatment of scleromyxoedema with hydroxychloroquine. J Dtsch Dermatol Ges 2003;1:30-5
   PubMedGoogle Scholar
• Caradonna S, Jacobe H. Thalidomide as a potential treatment for scleromyxedema. Arch Dermatol 2004;140:277-80
   PubMedGoogle Scholar
• Moller DR, Wysocka M, Greenlee BM, et al. Inhibition of IL-12 production by thalidomide. J Immunol 1997;159:5157-61
   PubMed Web of Science ®Google Scholar
• D'Amato RJ, Loughnan MS, Flynn E, et al. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1996;91:4082-5
   Google Scholar
• Tsirigotis P, Venetis E, Rontogianni D, et al. Thalidomide in the treatment of myelodysplastic syndrome with fibrosis. Leuk Res 2002;26:965-6
   PubMed Web of Science ®Google Scholar
• Barnhill RL, Doll NJ, Millikan LE, et al. Studies on the anti-inflammatory properties of thalidomide: effects on polymorphonuclear leukocytes and monocytes. J Am Acad Dermatol 1984;11:814-19
   PubMed Web of Science ®Google Scholar
• Hastings RC. Kellersberger memorial lecture 1979: immunosuppressive/anti-inflammatory thalidomide analogues. Ethiop Med J 1980;18:65-71
   PubMedGoogle Scholar
• Faure M, Thivolet J, Gaucherand M. Inhibition of PMN leukocytes chemotaxis by thalidomide. Arch Dermatol Res 1980;269:275-80
   PubMed Web of Science ®Google Scholar
• Atra E, Sato EI. Treatment of the cutaneous lesions of systemic lupus erythematosus with thalidomide. Clin Exp Rheumatol 1993;11:487-93
   PubMed Web of Science ®Google Scholar
• Davies FE, Raje N, Hideshima T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001;98:210-16
   PubMed Web of Science ®Google Scholar
• Shannon E, Noveck R, Sandoval F, et al. Thalidomide suppressed interleukin-6 but not tumor necrosis factor-alpha in volunteers with experimental endotoxemia. Transl Res 2007;150:275-80
   PubMed Web of Science ®Google Scholar
• Sampaio EP, Sarno EN, Galilly R, et al. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 1991;173:699-703
   PubMed Web of Science ®Google Scholar
• Sansbury JC, Cocuroccia B, Jorizzo JL, et al. Treatment of recalcitrant scleromyxedema with thalidomide in 3 patients. J Am Acad Dermatol 2004;51:126-31
   PubMed Web of Science ®Google Scholar
• Efthimiou P, Blanco M. Intravenous gammaglobulin and thalidomide may be an effective therapeutic combination in refractory scleromyxedema: case report and discussion of the literature. Semin Arthritis Rheum 2008;38:188-94
   PubMed Web of Science ®Google Scholar
• Pascualini MF, Caballero Escuti G, Valente E, et al. Response to thalidomide in scleromyxedema. Medicina (B Aires) 2013;73:252-4
   PubMed Web of Science ®Google Scholar
• Tseng S, Pak G, Washenik KP, et al. Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses. J Am Acad Dermatol 1996;35:969-79
   PubMed Web of Science ®Google Scholar
• Goz M, Eren MN, Cakir O. Arterial thrombosis and thalidomide. J Thromb Thrombolysis 2008;25:224-6
   PubMed Web of Science ®Google Scholar
• Yeung C-K, Loong F, Kwong Y-L. Scleromyxoedema due to a plasma cell neoplasm: rapid remission with bortezomib, thalidomide and dexamethasone. Br J Haematol 2012;157:411
   PubMed Web of Science ®Google Scholar
• Fett NM, Toporcer MB, Dalmau J, et al. Scleromyxedema and dermato–neuro syndrome in a patient with multiple myeloma effectively treated with dexamethasone and bortezomib. Am J Hematol 2011;86:893-6
   PubMed Web of Science ®Google Scholar
• Ataergin S, Arpaci F, Demiriz M, et al. Transient efficacy of double high-dose chemotherapy and autologous peripheral stem cell transplantation, immunoglobulin, thalidomide, and bortezomib in the treatment of scleromyxedema. Am J Clin Dermatol 2008;9:271-3
   PubMed Web of Science ®Google Scholar
• Bonnetblanc JM, Bedane C. Regression of scleromyxedema with topical betamethasone and dimethyl sulfoxide: a 30-month follow-up. Arch Dermatol 1991;127:1733-4
   PubMedGoogle Scholar
• Rongioletti F, Zaccaria E, Cozzani E, et al. Treatment of localized lichen myxedematosus of discrete type with tacrolimus ointment. J Am Acad Dermatol 2008;58:530-2
   PubMed Web of Science ®Google Scholar
• Jepsen LV. Two cases of scleromyxedema. Acta Derm Venereol 1980;60(1):77-9
   PubMedGoogle Scholar
• Kaufman D, Truhan AP, Roenigk HH Jr. Scleromyxedema: systemic manifestations and cosmetic improvement from dermabrasion. Cutis 1987;39:321-4
   PubMed Web of Science ®Google Scholar
• Acikel C, Karagoz H, Kucukodaci Z. Surgical treatment of facial disfigurement due to lichen myxedematosus. Dermatol Surg 2009;35:875-7
   PubMed Web of Science ®Google Scholar
• Kaymen AH, Nasr A, Grekin RC. The use of carbon dioxide laser in lichen myxedematosus. J Dermatol Surg Oncol 1989;15:862-5
   PubMedGoogle Scholar
• Zanna G, Fondevila D, Bardagí M, et al. Cutaneous mucinosis in shar-pei dogs is due to hyaluronic acid deposition and is associated with high levels of hyaluronic acid in serum. Vet Dermatol 2008;19:314-18
   PubMedGoogle Scholar